Pain reduction and tolerance of type II undenatured collagen in patients with knee osteoarthritis
DOI:
https://doi.org/10.18203/issn.2455-4510.IntJResOrthop20232607Keywords:
Native collagen, Osteoarthritis, Food SupplementAbstract
Background: Osteoarthritis (OA) is the most common cause of pain and disability in adults. Dietary supplements such as undenatured type II collagen (UC-II) have shown to have some benefits in OA treatment. This study aimed to assess changes in pain levels among knee OA patients treated with UC-II for 6 months.
Methods: Patients with knee OA of any grade were given a daily 40 mg dose of UC-II (CondroArtil®) as a dietary supplement for 6 months. Pain levels were measured using the visual analog scale (VAS) before starting UC-II 6 months thereafter. A total of 100 patients (62/38: male/female) with a mean age of 46.3±13.8 years participated in the study. Most patients (60%) had mild to moderate OA (grade I or II).
Results: The UC-II supplementation was shown to significantly reduce pain levels (p<0.001) with a negative correlation between pain reduction and age (p=0.006) and BMI (p=0.049). The OA severity also affected pain reduction (p=0.011), with grade II OA experiencing higher pain levels. Previous physical therapy and food supplements had a significant impact on pain reduction (p=0.017 and p=0.012, respectively).
Conclusions: The study suggests that UC-II is an effective treatment for reducing pain in patients with knee OA.
References
Glyn-Jones S, Palmer AJ, Agricola R, Price AJ, Vincent TL, Weinans H, Carr AJ. Osteoarthritis. Lancet. 2015;386(9991):376-87.
Das SK, Farooqi A. Osteoarthritis. Best Pract Res Clin Rheumatol. 2008;22(4):657-75.
Chevalier X, Richette P. Cartílago articular normal: anatomía, fisiología, metabolismo y envejecimiento. EMC. 2005;14:15.
Van Spil WE, DeGroot J, Lems WF, Oostveen JCM, Lafeber FPJG. Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. Osteoarthr Cartil. 2010;18(5):605-12.
Richette P, Poitou C, Garnero P, Vicaut E, Bouillot JL, Lacorte JM, et al. Benefits of massive weight loss on symptoms, systemic inflammation and cartilage turnover in obese patients with knee osteoarthritis. Ann Rheum Dis. 2011;70(1):139-44.
Uthman OA, Van der Windt DA, Jordan JL, Dziedzic KS, Healey EL, Peat JM, et al. Exercise for lower limb osteoarthritis: systematic review incorporating trial sequential analysis and network meta-analysis. BMJ. 2013;20:347.
Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012;64(4):465-74.
da Costa BR, Nüesch E, Reichenbach S, Jüni P, Rutjes AW. Doxycycline for osteoarthritis of the knee or hip. Cochrane Database Syst Rev. 2012;14(11):CD007323.
Bingham CO, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum. 2006;54(11):3494-507.
Laslett LL, Doré DA, Quinn SJ, Boon F, Ryan E, Winzenberg TM, et al. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann Rheum Dis. 2012; 71(8):1322-8.
Chevalier X, Goupille P, Beaulieu AD, Burch FX, Bensen WG, Conrozier T, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2009;61(3):344-52.
Nishida Y, Knudson CB, Knudson W. Osteogenic Protein-1 inhibits matrix depletion in a hyaluronan hexasaccharide-induced model of osteoarthritis. Osteoarthr Cartil. 2004.
Johnson K, Zhu S, Tremblay MS, Payette JN, Wang J, Bouchez LC, et al. A stem cell-based approach to cartilage repair. Science. 2012;336(6082):717-21.
Henrotin Y, Lambert C. Chondroitin and glucosamine in the management of osteoarthritis: an update. Curr Rheumatol Rep. 2013;15(10):361.
Crowley DC, Lau FC, Sharma P, Evans M, Guthrie N, Bagchi M, et al. Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial. Int J Med Sci. 2009;6:312-21.
Narayanan G. Understanding Collagen Supplements in Arthritis – Immunomodulation with Undenatured Collagen II Versus Cartilage Building with Hydrolysed Collagen II. Arch Orthoped Rheumatol. 2019;2(2): 2639-3654.
Weiner HL, da Cunha AP, Quintana F, Wu H. Oral tolerance. Immunol Rev. 2011:241(1):241-59.
Bagchi D, Misner B, Bagchi M, Kothari SC, Downs BW, Fafard RD, Preuss HG. Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: a mechanistic exploration. Int J Clin Pharmacol Res. 2002;22(4):101-10.
Lugo JP, Saiyed ZM, Lane NE. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study. Nutr J. 2016;15:14.
Asnagli H, Martire D, Belmonte N, Quentin J, Bastian H, Boucard-Jourdin M, et al. Type 1 regulatory T cells specific for collagen type II as an efficient cell-based therapy in arthritis. Arthritis Res Ther. 2014;16(3): R115.
Tong T, Zhao W, Wu YQ, Chang Y, Wang QT, Zhang LL, et al. Chicken type II collagen induced immune balance of main subtype of helper T cells in mesenteric lymph node lymphocytes in rats with collagen-induced arthritis. Inflamm Res. 2010;59(5):369-77.
D'Altilio M, Peal A, Alvey M, Simms C, Curtsinger A, Gupta RC, et al. Therapeutic Efficacy and Safety of Undenatured Type II Collagen Singly or in Combination with Glucosamine and Chondroitin in Arthritic Dogs. Toxicol Mech Methods. 2007;17(4): 189-96.
Deparle LA, Gupta RC, Canerdy TD, Goad JT, D'Altilio M, Bagchi M, Bagchi D. Efficacy and safety of glycosylated undenatured type-II collagen (UC-II) in therapy of arthritic dogs. J Vet Pharmacol Ther. 2005;28(4):385-90.
Gupta RC, Canerdy TD, Skaggs P, Stocker A, Zyrkowski G, Burke R, et al. Therapeutic efficacy of undenatured type-II collagen (UC-II) in comparison to glucosamine and chondroitin in arthritic horses. J Vet Pharmacol Ther. 2009;32(6):577-84.
Gupta RC, Lindley J, Barnes M, Minniear J, Goad JT, Canerdy TD, et al. Pain reduction measured by ground force plate in arthritic dogs treated with type-II collagen. Baltimore: Society of Toxicology; 2009.
Bagi CM, Berryman ER, Teo S, Lane NE. Oral administration of undenatured native chicken type II collagen (UC-II) diminished deterioration of articular cartilage in a rat model of osteoarthritis (OA). Osteoarthritis Cartilage. 2017;25(12):2080-90.
Gencoglu H, Orhan C, Sahin E, Sahin K. Undenatured Type II Collagen (UC-II) in Joint Health and Disease: A Review on the Current Knowledge of Companion Animals. Animals (Basel). 2020;10(4):697.
Varney JL, Fowler JW, Coon CN. Undenatured type II collagen mitigates inflammation and cartilage degeneration in healthy Labrador Retrievers during an exercise regimen. Transl Anim Sci. 2021;5(2):84.
Morley S, Williams AC, Eccleston C. Examining the evidence about psychological treatments for chronic pain: Time for a paradigm shift? Pain. 2013;154(10): 1929-31.
Bijur PE, Latimer CT, Gallagher EJ. Validation of a verbally administered numerical rating scale of acute pain for use in the emergency department. Acad Emerg Med. 2003;10(4):390-2.
Mehra A, Anand P, Borate M, Pal P, Kamble S, Metha KD, et al. A non-interventional, prospective, multicentric real life Indian study to assess safety and effectiveness of un-denatured type 2 collagen in management of osteoarthritis. Int J Res Orthop. 2019; 5(2):315-20.
Costa AV, Cunha Teixeira V, Pereira M, Mota Ferreira P, Kuplich PA, Dohnert MB, et al. Associated Strengthening Exercises to Undenatured Oral Type II Collagen (UC-II). Osteoarthr Nr. 2020;10(3):481-92.
Bakilan F, Armagan O, Ozgen M, Tascioglu F, Bolluk O, Alatas O. Effects of Native Type II Collagen Treatment on Knee Osteoarthritis: A Randomized Controlled Trial. Eurasian J Med. 2016;48(2):95-101.
Saiyed Z, Durkee S, Bowman J, Juturu V. Efficacy of UC-II ® Undenatured Type II Collagen on Knee Joint Function in Healthy Subjects: An Exploratory Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Trials. 2021;12:S15.
Yatish R, Naveenkumar L, Bilagi A, Joshi D. Evaluation of clinical efficacy of undenatured type ii collagen in the treatment of osteoarthritis of knee. A randomized controlled study. IJOS. 2020;6(2):497-500.
Lugo JP, Saiyed ZM, Lau FC, Molina JP, Pakdaman MN, Shamie AN, et al. Undenatured type II collagen (UC-II®) for joint support: a randomized, double-blind, placebo-controlled study in healthy volunteers. J Int Soc Sports Nutr. 2013;10(1):48.
Zhang W, Niu J, Chen C. Association between body mass index and knee osteoarthritis: a meta-analysis of observational studies. J Clin Rheumatol. 2018;24(3): 129-33.
van Dijk GM, Dekker J, Veenhof C, van den Ende CH; Carpa Study Group. Course of functional status and pain in osteoarthritis of the hip or knee: a systematic review of the literature. Arthritis Rheum. 2006;55(5): 779-85.
Kumar D, Kothari P, Kim J, Duan X, Bhargava A, Yu B, et al. Knee Osteoarthritis: A Review of Management Options. Korean J Pain. 2016;29(2): 77-84.
